Chronic kidney disease can affect hormone function in men and may contribute to lower testosterone levels, particularly as kidney disease becomes more advanced. Low testosterone is also more common in men with chronic illness, where inflammation, metabolic conditions, medications and changes in hormone signalling may all play a role.
For men considering testosterone replacement therapy (TRT) in Canada, kidney disease does not automatically mean treatment is off the table. However, TRT is not a treatment for kidney disease itself, and eligibility should be based on confirmed testosterone deficiency, symptoms, overall health and careful monitoring.
Men with chronic kidney disease may need closer assessment of kidney function, blood pressure, fluid status, hematocrit and cardiovascular risk before and during treatment.
Topics covered in this article:
Yes. Chronic kidney disease can contribute to low testosterone, particularly as kidney disease becomes more advanced.
Kidney disease can affect the hypothalamic-pituitary-gonadal axis, the hormone signalling system that helps regulate testosterone production. Chronic illness may disrupt signals between the brain, pituitary gland and testes, which can reduce testosterone production.
Several factors may contribute, including:
Low testosterone appears to be especially common in men with advanced chronic kidney disease and end-stage renal disease.
However, kidney disease should not automatically be assumed to be the only cause. A man with CKD and low testosterone may still need a broader evaluation to determine whether other hormonal, medical or medication-related factors are contributing.
Low testosterone in men with kidney disease can result from several overlapping effects of chronic illness on hormone production and signalling.
As kidney disease progresses, the hormonal signals that regulate testosterone may become disrupted. Uremia and chronic inflammation can interfere with normal communication between the hypothalamus, pituitary gland and testes.
The testes may also respond less effectively to hormonal stimulation, which can further reduce testosterone production.
Other factors may contribute as well. For example, prolactin levels can be altered in advanced kidney disease, while obesity, diabetes and other metabolic conditions are common in men with CKD and can independently affect testosterone levels.
Medications, poor nutritional status and the overall burden of chronic illness may also play a role.
For this reason, low testosterone in a man with kidney disease should be evaluated as part of the broader clinical picture rather than attributed to CKD alone.
Possibly. Kidney disease does not automatically rule out TRT, but treatment requires careful medical assessment.
Before TRT is considered, testosterone deficiency should be appropriately confirmed with symptoms and repeat testosterone testing.
A healthcare practitioner may also consider:
Men with more advanced CKD may require closer monitoring because kidney disease can affect blood pressure, fluid balance, cardiovascular risk and blood counts.
In some situations, especially with advanced CKD, dialysis or kidney transplantation, input from a nephrologist or other specialist may be appropriate before TRT is started or continued.
The decision should be individualized rather than based on kidney disease alone.
Current evidence does not show that TRT is inherently toxic to the kidneys, but safety depends on the individual and the severity of kidney disease.
Research specifically examining TRT in men with chronic kidney disease is more limited than the evidence available for the general hypogonadal population.
Small studies and reviews involving men with advanced kidney disease, dialysis or kidney transplantation have generally not identified clear evidence that appropriately prescribed TRT directly damages kidney function. However, the available evidence is still limited, and larger prospective studies are needed.
This means TRT should not be described as either harmful or protective to the kidneys in general.
In men with kidney disease, monitoring may be particularly important for:
TRT should therefore be considered on an individual basis, with the underlying kidney disease and overall medical risk taken into account.
TRT should not be expected to improve kidney function directly.
The purpose of TRT is to treat appropriately diagnosed testosterone deficiency, not to restore kidney function or treat chronic kidney disease.
Measures such as creatinine and estimated glomerular filtration rate (eGFR) are used to assess kidney function, but improving testosterone levels does not necessarily mean these measures will improve.
Some men may experience changes in symptoms, body composition or muscle mass after TRT, but these effects should not be interpreted as evidence that kidney disease itself is getting better.
Kidney function should continue to be monitored and managed according to the underlying renal condition, independently of whether TRT is being used.
Creatinine can change for several reasons during TRT and does not always mean kidney function has worsened.
Creatinine is a waste product produced from normal muscle metabolism. Because of this, blood creatinine levels can be influenced by muscle mass as well as kidney function.
If a man gains muscle during TRT, creatinine may rise modestly even when kidney function is stable. Hydration status can also affect the result, with dehydration sometimes making creatinine appear higher.
For men with chronic kidney disease, a single creatinine value should therefore be interpreted in context. A practitioner may look at:
A rise in creatinine should not automatically be assumed to mean that TRT has caused kidney damage or that CKD has progressed.
Possibly. More muscle mass can increase creatinine production without necessarily indicating kidney damage.
Creatinine is produced from creatine metabolism in muscle, so men with greater muscle mass may naturally have higher creatinine levels than men with less muscle.
If muscle mass increases during TRT, this can sometimes affect serum creatinine and, in turn, an eGFR calculation that is based on creatinine.
This is why kidney function should not be judged from one number alone. Trends over time, the broader clinical picture and other kidney markers may be considered when the creatinine result does not match the expected clinical picture.
In some situations, a practitioner may use additional testing to help clarify kidney function rather than relying only on creatinine-based eGFR.
Men with kidney disease may need broader baseline testing before TRT is started so that testosterone deficiency and overall treatment risk can be assessed.
Testing may include:
Additional hormone or endocrine testing may also be ordered if the cause of low testosterone is unclear.
The exact work-up depends on the stage of kidney disease, symptoms, other medical conditions and the individual treatment plan.
Kidney function during TRT is monitored by looking at trends in kidney markers together with blood pressure, fluid balance and the patient’s overall clinical status.
Monitoring may include:
The intensity of monitoring may differ depending on the severity of chronic kidney disease.
A man with mild, stable CKD may not need the same level of follow-up as someone with advanced disease, dialysis or a kidney transplant.
The most useful approach is to follow trends over time rather than interpreting one laboratory result in isolation.
TRT can cause fluid retention in some men, which may matter more in people with kidney or heart disease.
Fluid retention may appear as:
Men with chronic kidney disease may already have difficulty regulating fluid balance, so new or worsening edema during TRT deserves closer assessment.
Not every increase in body weight during TRT represents fluid retention. Changes in muscle mass, diet and overall body composition can also affect weight.
For this reason, sudden or unexplained weight gain should be considered together with swelling, blood pressure, breathing symptoms and kidney function.
TRT may affect blood pressure in some men, which is particularly important because blood-pressure control is already central to chronic kidney disease management.
High blood pressure can both contribute to kidney damage and result from impaired kidney function, so even modest changes may matter more in someone with CKD.
Potential contributors during TRT may include:
Men with kidney disease and hypertension should have blood pressure monitored before and during TRT, with treatment adjusted when clinically necessary.
Existing hypertension should be appropriately managed rather than assuming that TRT-related changes will resolve on their own.
Yes. Kidney disease can affect hematocrit, which can make blood-count monitoring during TRT more complex.
Chronic kidney disease can cause anemia, particularly as kidney function declines. One reason is that damaged kidneys may produce less erythropoietin, a hormone that helps stimulate red blood cell production.
TRT can have the opposite effect by increasing red blood cell production and raising hemoglobin and hematocrit in some men.
This means baseline blood counts in a man with CKD may reflect several overlapping factors, including:
For this reason, a complete blood count should be interpreted in the context of the man’s kidney disease, medications and treatment history.
TRT should not be assumed to correct anemia caused by chronic kidney disease simply because it can increase hematocrit.
No. TRT should not be used as a substitute for standard evaluation and treatment of CKD-related anemia.
Anemia in chronic kidney disease can result from reduced erythropoietin production, iron deficiency, inflammation, blood loss and other factors.
Although TRT can increase hemoglobin and hematocrit in some men, this effect does not make testosterone an appropriate treatment for CKD-related anemia.
Men with kidney disease and anemia may require a separate evaluation that can include blood counts, iron studies and other testing depending on the clinical situation.
Management of CKD-related anemia should remain part of the kidney-care plan, with nephrology involvement when appropriate.
TRT may be considered in some dialysis patients with confirmed testosterone deficiency, but evidence is limited and treatment requires individualized assessment.
Low testosterone is common in men with end-stage renal disease, including those receiving dialysis. Chronic illness, uremia, inflammation and altered hormone signalling can all contribute.
Research has explored whether TRT may improve symptoms, body composition or other outcomes in men receiving dialysis, but the available evidence remains limited.
Dialysis patients often have more complex medical needs, including:
For these reasons, TRT in a dialysis patient should not be approached the same way as TRT in an otherwise healthy man with uncomplicated hypogonadism.
Input from a nephrologist and other relevant specialists may be appropriate before treatment is started or continued.
TRT may be considered in selected kidney transplant recipients with confirmed testosterone deficiency, but treatment decisions should be individualized.
Testosterone levels may remain low in some men even after kidney transplantation.
The decision to use TRT should take into account:
Evidence specifically evaluating TRT after kidney transplantation is still limited.
Because transplant recipients may be taking multiple medications and require close monitoring of graft function, treatment should be coordinated with the healthcare team managing the transplant when appropriate.
Men with more advanced or medically complicated kidney disease may need closer assessment before and during TRT.
Extra caution may be appropriate in men with:
These factors do not automatically mean TRT is unsuitable, but they can change the balance of potential benefits, risks and monitoring needs.
The decision should be based on confirmed testosterone deficiency, CKD severity and the man’s overall medical condition.
There is not strong evidence that appropriately prescribed TRT directly accelerates chronic kidney disease, but kidney function still needs to be monitored in men with renal disease.
Research specifically examining long-term kidney outcomes with TRT in men with CKD remains limited.
TRT may indirectly affect factors that are important in kidney disease, including:
These effects do not mean TRT directly damages the kidneys, but they may matter more in someone whose kidney function is already impaired.
Creatinine, eGFR, blood pressure, fluid status and other relevant markers should therefore be followed over time rather than assuming kidney function will remain unchanged.
Not automatically. A rise in creatinine should be evaluated before deciding whether TRT needs to be changed or stopped.
Creatinine can increase for several reasons, including:
A practitioner may repeat the test, review previous creatinine and eGFR results and consider whether other kidney markers or clinical findings support a true decline in kidney function.
Symptoms, blood pressure, fluid status and medication changes may also help clarify the cause.
TRT should not be stopped or adjusted based on a single creatinine result without medical review.
Men with kidney disease should speak to a healthcare provider if they have low-testosterone symptoms, changes in kidney-function results or new symptoms during TRT.
Medical review is particularly important if you:
Sudden shortness of breath, severe swelling, very low urine output or other rapidly worsening symptoms may require more urgent assessment.
TRT should not be started, stopped or adjusted without practitioner guidance.
Yes. Chronic kidney disease can contribute to low testosterone, especially as kidney disease becomes more advanced.
Chronic illness, inflammation, uremia and changes in hormone signalling can all play a role.
Possibly. Kidney disease does not automatically prevent a man from receiving TRT.
Treatment should be based on confirmed testosterone deficiency, CKD severity, overall health and careful monitoring.
Current evidence does not show that appropriately prescribed TRT is inherently toxic to the kidneys, but CKD-specific evidence remains limited.
Safety depends on kidney-disease severity, cardiovascular risk, fluid status and other individual factors.
TRT is not intended to improve kidney function, and its effects on kidney markers should be interpreted in context.
Creatinine, eGFR, blood pressure and fluid status may need ongoing monitoring.
There is not strong evidence that TRT directly accelerates CKD, but it can affect factors such as blood pressure, fluid retention and hematocrit.
These factors may be especially important in men with existing kidney disease.
Creatinine may rise in some men during TRT, but this does not automatically mean kidney function has worsened.
Changes in muscle mass, hydration, medications and kidney function can all influence creatinine.
Yes, potentially. More muscle mass can increase creatinine production without necessarily indicating kidney damage.
Creatinine-based eGFR should therefore be interpreted alongside trends and the broader clinical picture.
TRT can indirectly affect creatinine-based eGFR if creatinine changes, but this does not necessarily reflect a true change in kidney filtration.
Practitioners may consider trends and additional kidney markers when results are unclear.
Testing may include creatinine, eGFR and electrolytes, along with a complete blood count and other tests based on CKD severity.
The exact monitoring plan should be individualized.
The frequency depends on the stage of kidney disease, baseline results and overall medical risk.
Men with advanced or unstable CKD generally require closer monitoring than those with mild, stable disease.
Yes. TRT can cause fluid retention in some men.
This may be more important in men with kidney disease, heart disease or existing edema.
TRT may affect blood pressure in some men, and blood-pressure monitoring is especially important in CKD.
Fluid retention and existing cardiovascular disease may further influence risk.
Yes. CKD can lower hemoglobin and hematocrit by contributing to anemia, while TRT can increase red blood cell production.
This makes blood-count interpretation more complex in some men with kidney disease.
No. TRT should not replace standard evaluation or treatment of CKD-related anemia.
Kidney-related anemia may require its own work-up and treatment strategy.
Some dialysis patients with confirmed testosterone deficiency may be considered for TRT, but treatment requires individualized assessment.
Because dialysis patients often have complex medical conditions, specialist involvement may be appropriate.
TRT may be considered in selected kidney transplant recipients with confirmed testosterone deficiency.
Graft function, medications, cardiovascular health and other transplant-related factors should be reviewed.
Yes. Low testosterone becomes more common as chronic kidney disease becomes more advanced.
Multiple hormonal and chronic-disease factors may contribute.
Not automatically. A rise in creatinine should first be evaluated to determine why it occurred.
Hydration, muscle changes, medications and the eGFR trend should all be considered before treatment is changed.
Men with advanced CKD, dialysis, a kidney transplant, uncontrolled hypertension, fluid overload or major cardiovascular risk may need closer monitoring.
The level of follow-up should reflect the individual’s overall health and kidney function.
New swelling, declining urine output, rising blood pressure, worsening shortness of breath or significant changes in kidney blood tests should be medically assessed.
Rapidly worsening symptoms may require urgent evaluation rather than waiting for a routine TRT follow-up.